PCBP4

Across TCGA pan-cancer cohorts, PCBP4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PCBP4 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PCBP4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PCBP4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where PCBP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	1.000	0.765	.033	6	view →
PDAC	DFS	Quartile	II,III,IV	0.535	0.280	.016	6	view →
UCEC	OS	Tertile	All	0.865	0.978	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PCBP4–LUAD (DFS)

Open the LUAD breakdown →